Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.15%178.040.7%$1349.93m
MRKMerck & Co., Inc. -0.24%92.910.7%$1225.40m
PFEPfizer Inc. 0.33%52.930.9%$1135.52m
LLYEli Lilly & Co. -0.53%328.401.1%$1006.20m
BMYBristol-Myers Squibb Co. -0.76%75.641.0%$976.39m
ABBVAbbVie, Inc. -0.44%151.861.9%$956.34m
AZNAstraZeneca Plc 0.01%66.501.0%$467.37m
SGENSeagen Inc. 2.49%179.495.7%$331.94m
GSKGSK Plc 0.51%43.330.2%$274.24m
TPTXTurning Point Therapeutics, Inc. 0.11%75.260.0%$179.28m
NVSNovartis AG 0.66%84.290.2%$174.63m
HZNPHorizon Therapeutics Plc 2.07%84.185.4%$174.56m
ALNYAlnylam Pharmaceuticals, Inc. 1.23%151.858.1%$148.36m
NVONovo Nordisk A/S -0.62%109.800.1%$147.56m
MRTXMirati Therapeutics, Inc. -0.53%69.461.6%$138.17m

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.